BioSpace News Archive

Time for progress in reducing emissions or risk human lives and viability of health systems says new Lancet Countdown report

Canada’s slow progress in reducing greenhouse gas emissions is having a significant impact on the physical and mental health of Canadians, suggests a new brief published today by the Lancet Countdown on Health and Climate Change.

November 28, 2018
·
5 min read
Policy

Statement - The Canadian Medical Association (CMA) pushes to make climate change a health priority

The Canadian Medical Association (CMA) joins the Canadian Public Health Association (CPHA) in calling for the implementation of the Canada-specific recommendations presented in the Lancet Countdown on Health and Climate Change.

November 28, 2018
·
1 min read
Biotech Beach

Macy’s Raises $1Million For The Elizabeth Taylor AIDS Foundation

This grant will be used for programs all across the United States, supporting three 2019 ETAF priorities: families and children, women, and young people.

November 28, 2018
·
2 min read
FDA

XOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation

FLT3 mutation-positive AML is a life-threatening disease[1] with significant unmet medical needs

November 28, 2018
·
13 min read
Policy

Information Update - Mylan-Valsartan medications voluntarily recalled as a precaution due to an impurity

Mylan Pharmaceuticals ULC is voluntarily recalling four lots of Mylan-Valsartan tablets (40 mg, 80 mg, 160 mg and 320 mg strength) after testing found low levels of an impurity, N-nitrosodiethylamine (NDEA).

November 28, 2018
·
3 min read
Business

UNH Researchers Create a More Effective Hydrogel For Healing Wounds

Researchers at the University of New Hampshire have created an easy-to-make, low-cost injectable hydrogel that could help wounds heal faster, especially for patients with compromised health issues.

November 28, 2018
·
2 min read
Drug Development

MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA) to Evaluate Guselkumab in Hidradenitis Suppurativa

MorphoSys AG announced today that its licensee Janssen Research & Development, LLC (Janssen) initiated a phase 2 clinical study of guselkumab in patients with moderate to severe hidradenitis suppurativa (HS), a chronic skin disease also known as acne inversa.

November 28, 2018
·
6 min read
Job Trends

Treating a Rare Genetic Disorder That Causes Colon Cancer in Children

UH Pharmaceutical Scientist Eyeing New Drug that Recycles Through the Colon

November 28, 2018
·
3 min read
Drug Development

NOXXON TO LAUNCH NOX-A12 WITH RADIOTHERAPY CLINICAL TRIAL IN PATIENTS WITH BRAIN CANCER

New therapeutic combination is expected to be generally applicable to many solid tumors with high unmet medical need

November 28, 2018
·
5 min read
Environmental exposures early in life modify immune responses – effects visible even in adolescence

The prevalence of allergic diseases has increased significantly over the last decades, creating substantial financial and societal burdens. Due to this, researchers are trying to discover new approaches to the prevention and treatment of these diseases.

November 28, 2018
·
4 min read